BioNTech SE (BNTX)

NMS – Real vaqt narxi. Valyuta: USD

91.22

+1.22 (1.36%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

90.50

-0.72 (-0.79%)

Bozordan keyin: Jun 26, 2026, 7:18 PM EDT

17.06.2026

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

U.S. pharmaceutical company Moderna is interested ‌in investing in production facilities in Germany, with an eye on ⁠plants that its German rival BioNTech plans to close, CEO Stephane Bancel told the German business daily Handelsblatt ‌on ⁠Wednesday.

04.06.2026

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.

01.06.2026

Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO

BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.

30.05.2026

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of care Pumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypes Pumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial, along with two additional global Phase 3 trials MAINZ, Germany, and PRINCETON, USA, May 30, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced interim Phase 2 data from the global Phase 2/3 ROSETTA Lung-02 clinical trial (NCT06712316) evaluating the investigational PD-L1xVEGF-A bispecific immunomodulator pumitamig (also known as BNT327 or BMS-986545) plus chemotherapy in patients with previously untreated advanced non-small cell lung cancer (“NSCLC”). The data showed encouraging anti-tumor activity, with high response rates observed in both non-squamous and squamous NSCLC and at each PD-L1 expression level (TPS ˂ 1%, TPS 1 – 49%, and TPS ≥ 50%).

27.05.2026

This Biotech's Cancer Portfolio Could End Its Rough Patch

The drugmaker is looking to its oncology pipeline to drive its next leg of growth.

22.05.2026

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

Pumitamig data from the ongoing Phase 2/3 ROSETTA Lung-02 trial in first-line non-small cell lung cancer mark the third global data set to consistently show encouraging anti-tumor activity for pumitamig in combination with chemotherapy Gotistobart Phase 2 overall survival data in patients with platinum-resistant ovarian cancer add to the growing body of evidence supporting its potential as a chemotherapy-free treatment option Continued advancement of late-stage oncology pipeline with 25+ Phase 2 and Phase 3 clinical trials, including 13 ongoing pivotal trials as well as novel-novel combination trials across major cancer types MAINZ, Germany, May 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present new clinical data and trial updates from its late-stage oncology pipeline and innovative combination programs at the 2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting held in Chicago, from May 29 to June 02. Two oral presentations will highlight new data for key strategic assets pumitamig and gotistobart.

15.05.2026

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

MAINZ, Germany, May 15, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) held its Annual General Meeting (“AGM”) today. A total of 92 per cent of the share capital was represented at the virtual assembly.

Videolar

01.08.2025

Positive

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

01.08.2025

Negative

President Trump demands drugmakers slash prices within 60 days

Press-relizlar

30.05.2026

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

22.05.2026

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

15.05.2026

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

07.05.2026

BioNTech Announces New ADS Repurchase Program

MAINZ, Germany, May 7, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that it has authorized a new share repurchase program (the “Program”), under which the Company may repurchase American Depositary Shares (“ADSs”), each representing one ordinary share of the Company, for an aggregate amount of up to $1.0 billion. Repurchases under the Program may be made until and including May 6, 2027.

BioNTech SE (BNTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BioNTech SE (BNTX)

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

This Biotech's Cancer Portfolio Could End Its Rough Patch

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

Videolar

Press-relizlar

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

BioNTech Announces New ADS Repurchase Program

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

This Biotech's Cancer Portfolio Could End Its Rough Patch

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

Videolar

Press-relizlar

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

BioNTech Announces New ADS Repurchase Program

Search stocks

BioNTech SE (BNTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BioNTech SE (BNTX)

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

This Biotech's Cancer Portfolio Could End Its Rough Patch

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

Videolar

Press-relizlar

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

BioNTech Announces New ADS Repurchase Program

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study

Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

This Biotech's Cancer Portfolio Could End Its Rough Patch

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

Videolar

Press-relizlar

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

BioNTech Announces New ADS Repurchase Program